Latest: Watch here for details of new products and services.
- About Us
- Pharmalicensing - Open Innovation for the life sciences
- Our Products
- Overview
- Partnering Search
- Company Profiling
- Partneringtools
- Reports
- Partnering Consulting
- Due Diligence
- Comparison
- Due Diligence
- Overview
- Top Applications
- Online Panel Discussions
- Request Consultation
- Case Studies
- See what others think about our service
- Newsletter
- Partnering update
- Key reports
- Subscribe
- Quick Links
- Profile now
- Register now
- Profiled companies
- Featured events
- Industry news
- PR Newswire
- Jobs
- Forums
- Contact Pharmalicensing
- Send an email
- Call us: +44 1904 520460
- Request a callback
- RSS Feeds
- Keep up to date
Pharmalicensing Ltd
is a division of
is a division of
Up-to-date access to technology licensing opportunities worldwide.
- Out-licensing
- Browse
Licensing opportunities
A liquid system which enables rapid transmigration of therapeutic doses of up to large molecules More
Researchers at the University of Western Ontario have developed a Pulmonary Drug Delivery Technology Suite comprised of two innovative inventions for the precision measurement and dispensing of micro fine, dry powders. More
Coupling drug substances with hydroxyethyl starch (HES) derivatives to improve pharmacokinetics and pharmacodynamics. More
Phytohealth Corporation: PH3 (PHN031, PHN033) - For osteoporosis and diabetic vascular complications
Patented technology regarding new and safe mechanism with the active substance PH3 for the indications of osteoporosis and diabetic vascular complications. More
The University of Edinburgh has perfected a genetic engineering strategy in mouse embryonic stem cells to replace large regions of mouse chromosomal sequences (>100kb) with the corresponding human syntenic region. More
This ophthalmic solution provides relief of the symptoms associated with dry eye, improving the quality of life among sufferers in both mild-moderate and chronic dry eye cases. More
The present invention provides a potent inhibitor of protein glycation and AGEs formation that is particularly advantageous for eye-drop delivery in the prevention and treatment of diabetes- and age-related pathologies. More
L-histidine is being developed as a prescription drug and as a dietary supplement for 1) chronic inflammatory gastrointestinal diseases; 2) conjunctivitis and seasonal allergic rhinitis; 3) infectious and non-infectious diarrheas; and 4) as an antioxidant More
Indicated specifically for subarachnoid hemorrhage, LPCN 1038 also has potential indications for migraine prophylaxis and glaucoma. More
Effective treatment options for diseases such as Alzheimer's, Parkinson's, and cataracts are needed. This new group of compounds have the potential to treat disorders caused by oxidative stress by functioning as antioxidants and metal chelators. More
Your selection
Browse By
- Industry sector
- Generics
- Nutrition
- OTC/Non-Prescription
- Pediatric
- Personal Care
- Prescription
- Therapeutic target
- Auditory
- Opthalmic
- Development phase
- Early Stage
- Preclinical
- Phase I
- Phase I/II
- Phase II
- Phase III
- Phase III/IV
- Preregistration
- Registered
© Copyright 1995-2008 Pharmalicensing Ltd, is a division of 
All rights reserved. Terms and Conditions | Site map | Contact us